AURA
HealthcareAura Biosciences, Inc.
$5.18
$-0.12 (-2.26%)
Jan 5, 2026
Price History (1Y)
Analysis
Aura Biosciences, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $328.95 million and 106 employees. The company's financial health indicates significant losses, with net income totaling -$106,466,000 and EBITDA of -$112,213,000 over the trailing twelve months. The firm also reports negative returns on equity (-64.3%) and assets (-35.8%). Aura Biosciences has a substantial cash balance of $161.87 million but carries relatively low debt of $17.75 million, resulting in a debt-to-equity ratio of 11.33. Aura Biosciences' valuation is characterized by a negative forward P/E ratio of -2.55 and a price-to-book ratio of 2.08. The company's market capitalization and cash balance suggest it has some financial resources to support its operations, but the significant losses and low profitability margins (0.0% gross, operating, and profit margin) raise concerns about its long-term viability.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Aura Biosciences, Inc.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $328.95M
- P/E Ratio
- N/A
- 52-Week High
- $8.47
- 52-Week Low
- $4.34
- Avg Volume
- 232.57K
- Beta
- 0.46
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 106